Genoway

Genoway Capital Intensity

The Capital Intensity Ratio of Genoway (ALGEN.PA) as of Oct 21, 2026 is 216.43 %. In the previous year, Capital Intensity Ratio was 144.16 % — a change of 50.13% (higher).

Capital Intensity

216.43 %

YoY

50.13%

Last updated:

Capital Intensity Ratio of Genoway is 2025 216.43 % . Capital Intensity Ratio of Genoway was 2024 144.16 % . It decreases by 50.13% higher compared to the previous year.

The Genoway Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
131.66 EUR
Jan 1, 2019
134.14 EUR
Jan 1, 2020
250.27 EUR
Jan 1, 2021
231.81 EUR
Jan 1, 2022
193.06 EUR
Jan 1, 2023
158.84 EUR
Jan 1, 2024
144.16 EUR
Jan 1, 2025
216.43 EUR
The Genoway Capital Intensity history
YEARCapital IntensityYoY
216.43 %+50.13%
144.16 %-9.24%
158.84 %-17.72%
193.06 %-16.71%
231.81 %-7.38%
250.27 %+86.57%
134.14 %+1.88%
131.66 %+0.96%
130.42 %+28.60%
101.41 %-4.65%
106.36 %-1.25%
107.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

Capital Intensity Ratio of Genoway is 216.43 % in 2025.

Capital Intensity Ratio of Genoway changed from 144.16 % to 216.43 %, representing a 50.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Genoway since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Genoway with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genoway

All Key Metrics — Genoway